| Document |
Document Title |
|
WO/2006/100563A1 |
Methods and reagents for transition metal-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for ...
|
|
WO/2006/092204A1 |
The invention relates to a new class of compounds with action inhibiting carnitine palmitoyl transferase (CPT), pharmaceutical compounds which contain at least one new compound according to the invention, and their therapeutic use in the...
|
|
WO2006074025B1 |
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...
|
|
WO/2006/089952A1 |
The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.
|
|
WO/2006/084688A1 |
Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.
|
|
WO/2006/083924A1 |
1-Acylamino-2-hydroxy-3-amino-&ohgr -arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.
|
|
WO/2006/083266A1 |
In accordance with the present invention, compounds having formula (I), where the variables are as identified in the claims, that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect ...
|
|
WO/2006/069690A1 |
The invention relates to radiation-hardenable compounds, methods for the production thereof and the use thereof, in addition to highly scratch-resistant coating materials containing said compounds.
|
|
WO/2006/063653A1 |
The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.
|
|
WO/2006/063654A1 |
The invention relates to a method for producing onium alkyl sulfates by reacting an onium halogenide with a symmetrically substituted dialkyl sulfate, the alkyl group thereof containing between 1 and 14 C atoms, with an unsymmetrically s...
|
|
WO/2006/062580A1 |
The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.
|
|
WO/2006/052722A1 |
The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/o...
|
|
WO/2006/050800A1 |
Compounds of formula (I), where R6, R7, R8, R9, Het1, X and X' have the meanings given in claim 1 are tyrosine kinase inhibitors, in particular, of TIE-2, and Raf kinases and can be used, amongst other things, for the treatment of tumours.
|
|
WO/2006/049264A1 |
There are provided a novel ethylenically unsaturated group-containing isocyanate compound, a process for producing the same, and a reactive monomer produced from the isocyanate compound, a reactive polymer and its use. The ethylenically ...
|
|
WO/2006/041841A1 |
Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be...
|
|
WO/2006/040625A1 |
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the...
|
|
WO/2006/037468A1 |
Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein T is O or S; U is O, S, N(R4), or a direct bond linking V to the C(=T) moiety; V is optionally substituted C1-6 alkylene; W is C(O)N(R5) or a direct bond linking ...
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/037574A1 |
The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (I I) in a sin...
|
|
WO2005122379A9 |
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...
|
|
WO/2006/023457A1 |
This invention provides compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this ...
|
|
WO/2006/018326A1 |
The invention relates to novel biaromatic compounds that correspond to the general formula (I) and also to the method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine (in dermato...
|
|
WO/2006/015852A1 |
Compounds of formula (I) in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergi...
|
|
WO/2006/017216A1 |
This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, aut...
|
|
WO/2006/010362A1 |
The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention als...
|
|
WO/2006/011420A1 |
Disclosed is a compound represented by the general formula (1) below. (1) [In the formula, R represents a hydrogen atom or a lower alkyl group; X represents a sulfur atom or an oxygen atom; Y represents a chain, branched or cyclic alkyl ...
|
|
WO2005113511A9 |
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...
|
|
WO/2006/006725A1 |
The present invention provides a reversible thermosensitive recording medium including a support and a thermosensitive recording layer thereon, in which the thermosensitive recording layer comprises an electron-donating coloring compound...
|
|
WO/2006/003923A1 |
Disclosed is an excellent LXR modulator. Specifically disclosed are compounds represented by the following general formula (I). (In the formula, R1 represents -COR9 (wherein R9 represents an alkyl, an optionally substituted alkoxy or an ...
|
|
WO/2006/002474A1 |
Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The b...
|
|
WO/2005/123666A1 |
The invention relates to compounds of formula (I), wherein R e R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.
|
|
WO/2005/114331A1 |
A resist composition which comprises one or more resist compounds (A) satisfying all of the requirements of (a) having, in the molecule thereof, at least one crosslinking group undergoing a crosslinking reaction directly or indirectly by...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/108352A1 |
The invention relates to novel biaromatic compounds which correspond to the following general formula (I) and to their method of preparation and to their use in pharmaceutical compositions intended for use in human or veterinary medicine...
|
|
WO/2005/108370A1 |
It is intended to provide benzene compounds represented by the following formulae and analogs thereof which exert an ACC activity inhibitory effect and are efficacious in treating hyperlipemia, fatty liver, impaired glucose tolerance, di...
|
|
WO/2005/105737A1 |
The present invention relates to novel processes for the preparation of substituted tetralin and substituted indane derivatives. The present invention is further directed to novel processes for the preparation of intermediates in the pre...
|
|
WO/2005/097737A1 |
The invention relates to a method for producing polyisocyanate prepolymers comprising allophanate structural units, using zinc compounds as catalysts and to the use of said prepolymers for producing polyurethanes and polycarbamides.
|
|
WO/2005/097773A1 |
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...
|
|
WO/2005/095333A1 |
The present invention relates to polymorphic forms of (1-&lcub 3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl&rcub -ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester, processes therein, pharmaceutical compositions thereof, and uses therewith.
|
|
WO/2005/092843A1 |
This invention relates to novel urea derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases ...
|
|
WO/2005/092841A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/090288A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO/2005/085180A1 |
A novel method of an amidocarbonylation reaction among an aldehyde compound, an amide compound, and carbon monoxide, which comprises using a palladium-supporting crosslinked-polymer composition containing palladium clusters having a majo...
|
|
WO/2005/082862A2 |
The present invention relates to benzimidazolyl derivatives of formula (I), with the definitions of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the u...
|
|
WO/2005/075410A1 |
Compounds of formula (I), for clinical treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia. A pharmaceutical composition comprising a compound of formula (I) in an amount giving a d...
|
|
WO/2005/070871A2 |
The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5, X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these ...
|
|
WO/2005/068417A1 |
A triphenylmethane derivative represented by the general formula (1), an organic gallant containing the derivative, an organic gel, and an organic fiber. Although the triphenylmethane derivative is a low-molecular compound, it has the ab...
|
|
WO/2005/068420A1 |
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...
|
|
WO/2005/063699A1 |
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected ...
|
